Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)-Reference-Cited by-同舟云学术

Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

Published:2018-04-19 Issue:5 Volume:178 Page:e332-e341
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Chalmers J.R.¹,Thomas K.S.¹,Apfelbacher C.²,Williams H.C.¹,Prinsen C.A.³,Spuls P.I.⁴,Simpson E.⁵,Gerbens L.A.A.⁴,Boers M.⁶,Barbarot S.⁷,Stalder J.F.⁷,Abuabara K.⁸,Aoki V.⁹,Ardeleanu M.¹⁰,Armstrong J.¹¹,Bang B.¹²,Berents T.L.¹³,Burton T.¹⁴,Butler L.¹⁵,Chubachi T.¹⁶,Cresswell-Melville A.¹⁷,DeLozier A.¹⁸,Eckert L.¹⁹,Eichenfield L.²⁰,Flohr C.²¹,Futamura M.²²,Gadkari A.¹⁰,Gjerde E.S.²³,van Halewijn K.F.²⁴,Hawkes C.²⁵,Howells L.¹,Howie L.²⁶,Humphreys R.²⁷,Ishii H.A.²⁸,Kataoka Y.²⁹,Katayama I.³⁰,Kouwenhoven W.³¹,Langan S.M.³²,Leshem Y.A.³³,Merhand S.³⁴,Mina-Osorio P.¹⁰,Murota H.³⁵,Nakahara T.³⁶,Nunes F.P.¹⁸,Nygaard U.¹⁸,Nygårdas M.³⁷,Ohya Y.³⁸,Ono E.³⁰,Rehbinder E.³⁹,Rogers N.K.¹,Romeijn G.L.E.⁴⁰,Schuttelaar M.L.A.⁴⁰,Sears A.V.²¹,Simpson M.A.⁴¹,Singh J.A.⁴²,Srour J.⁴³,Stuart B.⁴⁴,Svensson Å.⁴⁵,Talmo G.⁴⁶,Talmo H.⁴⁶,Teixeira H.D.⁴⁷,Thyssen J.P.⁴⁸,Todd G.⁴⁹,Torchet F.³⁴,Volke A.⁵⁰,von Kobyletzki L.⁵¹⁵²⁵³⁵⁴⁵⁵,Weisshaar E.⁵⁶,Wollenberg A.⁵⁷,Zaniboni M.⁵⁸

Affiliation:

1. Centre of Evidence Based Dermatology; University of Nottingham; Nottingham U.K.

2. Medical Sociology; Institute of Epidemiology and Preventive Medicine; University of Regensburg; Regensburg Germany

3. Department of Epidemiology and Biostatistics; EMGO+ Institute for Health and Care Research; VU University Medical Center; Amsterdam the Netherlands

4. Department of Dermatology; Academic Medical Center; Amsterdam the Netherlands

5. Department of Dermatology; Oregon Health and Science University; Portland OR U.S.A.

6. VU University Medical Center; Amsterdam the Netherlands

7. Department of Dermatology, Nantes University Hospital (CHU de Nantes); France

8. Department of Dermatology; University of California San Francisco; San Francisco CA U.S.A.

9. University of São Paulo Medical School; São Paulo Brazil

10. Regeneron Pharmaceuticals; Tarrytown NY U.S.A.

11. Galderma; Paris France

12. LEO Pharma; Ballerup Denmark

13. Oslo University Hospital; Oslo Norway

14. Patient; Nottingham U.K.

15. National Eczema Association; San Rafael CA U.S.A.

16. GlaxoSmithKline; Research Triangle Park NC U.S.A.

17. Eczema Society of Canada; Keswick ON Canada

18. Eli Lilly and Company; Indianapolis IN U.S.A.

19. Sanofi; Chilly-Mazarin France

20. Rady Children's Hospital; University of California San Francisco; San Diego CA U.S.A.

21. St John's Institute of Dermatology; St Thomas’ Hospital; London U.K.

22. Nagoya Medical Center; Nagoya Japan

23. The Psoriasis and Eczema Association of Norway; Oslo Norway

24. Erasmus MC; University Medical Centre; Rotterdam the Netherlands

25. GlaxoSmithKline; Uxbridge U.K.

26. Global Parents for Eczema Research; Brisbane Australia

27. National Eczema Society; London U.K.

28. Brazilian Atopic Dermatitis Association (AADA); São Paulo Brazil

29. Osaka Prefectural Medical Center for Respiratory and Allergic Disease; Osaka Japan

30. Osaka University; Osaka Japan

31. Dutch Association for People with Atopic Dermatitis; Nijkerk the Netherlands

32. Faculty of Epidemiology and Population Health; London School of Hygiene and Tropical Medicine; London U.K.

33. Beilinson Hospital and Tel Aviv University; Petah Tikva and Tel Aviv Israel

34. Association Française de l'Eczéma; Redon France

35. Department of Dermatology; Osaka University; Suita Japan

36. Department of Dermatology; Kyushu University; Fukuoka Japan

37. Sanofi Genzyme; Stockholm Sweden

38. National Centre for Child Health and Development; Tokyo Japan

39. Department of Dermatology; Oslo University Hospital; Oslo Norway

40. Department of Dermatology; University of Groningen; University Medical Center Groningen; Groningen the Netherlands

41. Dermavant Sciences, Inc.; Durham NC U.S.A.

42. Department of Medicine, University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center; Birmingham AL U.S.A.

43. Klinik und Poliklinik für Dermatologie und Allergologie der LMU - München; Munich Germany

44. Primary Care and Population Sciences Division; University of Southampton; Southampton U.K.

45. Department of Dermatology and Venereology; Lund University; Malmö Sweden

46. The Psoriasis and Eczema Association of Norway; Haugesund Norway

47. AbbVie Inc.; North Chicago IL U.S.A.

48. Department of Dermatology and Allergy; Herlev and Gentofte Hospital; Hellerup Denmark

49. University of Cape Town; Cape Town South Africa

50. Department of Dermatology; University of Tartu; Tartu Estonia

51. Department of Dermatology; Lund University; Skåne University Hospital; Malmö Sweden

52. Department of Public Health Sciences; Karlstad University; Karlstad Sweden

53. CF Wahlgren, Dermatology Unit; Department of Medicine Solna; Karolinska Institutet; Stockholm Sweden

54. Karolinska University Hospital; Stockholm Sweden

55. Department of Dermatology, Venereology and Allergy University Hospital Schleswig-Holstein; Kiel Germany

56. Department of Social Medicine, Occupational and Environmental Dermatology; Ruprecht Karls University; Heidelberg Germany

57. Ludwig-Maximilian University; Munich Germany

58. University of São Paulo; Campinas Brazil

Funder

Université de Nantes

Chung Hua University

Department of Dermatology CHU Nantes

University of Nottingham

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.16543/fullpdf

Reference17 articles.

1. Developing core outcome sets for clinical trials: issues to consider;Williamson;Trials,2012

2. The COMET Handbook: version 1·0;Williamson;Trials,2017

3. The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology;Schmitt;J Invest Dermatol,2015

4. How to select outcome measurement instruments for outcomes included in a ‘Core Outcome Set’ - a practical guideline;Prinsen;Trials,2016

5. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME);Chalmers;Br J Dermatol,2014

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical severity measures and patient‐reported outcomes in atopic dermatitis;Journal of the European Academy of Dermatology and Venereology;2023-12-29

2. A Mini Review of the Impact of Baseline Disease Severity on Clinical Outcomes: Should We Compare Atopic Dermatitis Clinical Trials?;Dermatology and Therapy;2023-11-02

3. Physician practices and attitudes towards atopic dermatitis in Latin America: A cross-sectional study;World Allergy Organization Journal;2023-11

4. Treat‐to‐target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis;Journal of the European Academy of Dermatology and Venereology;2023-09-21

5. Abrocitinib effect on patient‐reported outcomes in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study;Journal of the European Academy of Dermatology and Venereology;2023-07-17